Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands.
Improvements in our understanding of the functions of peroxisome proliferator-activated receptor (PPAR) subtypes as master regulators of many biological functions have made it possible to develop novel PPAR ligands with characteristic subtype selectivity as biochemical tools and/or candidate drugs for the treatment of PPAR-dependent diseases such as metabolic syndrome, which includes type II diabetes, dyslipidemia, obesity, hypertension, and inflammation. Based on the findings that the glitazone-class antidiabetic agents, and fibrate-class antidyslipidemic agents are ligands of PPARgamma and PPARalpha respectively, much research interest has been focused on these two subtypes as therapeutic targets for the treatment of type II diabetes and dyslipidemia. In contrast, research interest in PPARdelta has been limited. However, since 2001, the availability of PPARdelta knockout animals and selective ligands has led to the uncovering of possible roles of PPARdelta in fatty acid metabolism, insulin resistance, reverse cholesterol transport, inflammation, and so on. It has become clear that ligands able to modulate PPARdelta-mediated pathways are candidates for the treatment of altered metabolic function. This review focuses on recent medicinal chemical studies to identify PPARdelta-selective agonists.
Miyachi
Hiroyuki
H
Institute of Molecular and Cellular Biosciences, University of Tokyo, Japan. miyachi@iam.u-tokyo.ac.jp
D015195:Drug Design; D006801:Humans; D008024:Ligands; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000378:metabolism; D047494:PPAR delta / Q000819:agonists* / Q000378:metabolism*; D020675:Peroxisomes / Q000378:metabolism; D013329:Structure-Activity Relationship
D008024:Ligands; D047494:PPAR delta